Galectin Therapeutics Inc - Asset Resilience Ratio
Galectin Therapeutics Inc (GALT) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Galectin Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2017)
This chart shows how Galectin Therapeutics Inc's Asset Resilience Ratio has changed over time. See GALT net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Galectin Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Galectin Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Galectin Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Galectin Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Galectin Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Galectin Therapeutics Inc (2006–2017)
The table below shows the annual Asset Resilience Ratio data for Galectin Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $4.16 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $15.79 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $26.41 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $29.68 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $10.71 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $9.56 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $6.61 Million | -- |
| 2006-12-31 | 78.58% | $5.00 Million | $6.36 Million | -- |
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 cl… Read more